Urinary Excretion of Aminohydroxypropylidene Bisphosphonate in Cancer Patients after Single Intravenous Infusions

This publication has 12 references indexed in Scilit:

• Cancer-Associated Hypercalcemia: Morbidity and Mortality
  Annals of Internal Medicine, 1990
• Increased Serum Levels of a Parathyroid Hormone-like Protein in Malignancy-Associated Hypercalcemia
  Annals of Internal Medicine, 1989
• Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia
  Cancer, 1989
• Treatment of Tumor-Induced Osteolysis by APD
  Published by Springer Nature ,1989
• Current Management of Malignant Hypercalcaemia
  Drugs, 1988
• Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy
  BMJ, 1988
• Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride
  The American Journal of Medicine, 1987
• The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats
  Calcified Tissue International, 1970
• Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo
  Science, 1969
• Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo
  Science, 1969